Taipei, Taiwan, Dec. 16, 2025 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced initiation of its latest plans for new facilities and a U.S. operations center in California to accelerate clinical development, regulatory engagement and commercial access for next‑generation diagnostics and exosome‑based therapeutics. The California operations center i ...

Core Insights - Silexion Therapeutics has initiated a regulatory application in Israel for its Phase 2/3 clinical trial of SIL204 targeting locally advanced pancreatic cancer, marking a significant milestone in its clinical development program [1][2][4] - The application is supported by successful toxicology studies and positive feedback from German regulatory authorities, with plans for further regulatory filings in Germany and the EU in Q1 2026 [1][2][4] - The planned Phase 2/3 trial aims to evaluate SIL204's dual-route administration strategy, which combines intratumoral delivery and systemic administration [4] Company Overview - Silexion Therapeutics is a clinical-stage biotechnology company focused on RNA-based therapies for oncology, particularly targeting cancers with mutated KRAS oncogenes [5] - The company previously conducted a Phase 2a clinical trial for its first-generation product, which showed a positive trend compared to chemotherapy alone [5] Clinical Development - The Phase 2/3 trial is set to begin in Q2 2026, following the completion of a safety run-in in Israel and Germany [2][4] - The collaboration with Sheba Medical Center, a top-ranked hospital, is integral to the Israeli portion of the clinical trial [3]

Core Insights - Two stocks in the health care sector are signaling potential warnings for momentum-focused investors as of December 16, 2025 [1] Group 1: Avidity Biosciences Inc (NASDAQ:RNA) - Avidity Biosciences reported quarterly losses of $1.27 per share, missing the analyst consensus estimate of losses of $1.11 per share [5] - The company reported quarterly sales of $12.475 million, exceeding the analyst consensus estimate of $1.932 million [5] - Avidity's stock has gained approximately 141% over the past six months, with a 52-week high of $71.90 [5] - The RSI value for Avidity is 76, indicating it is considered overbought [5] - Avidity's shares closed at $71.86, with a momentum score of 95.79 [5] Group 2: Henry Schein Inc (NASDAQ:HSIC) - Barclays analyst Glen Santangelo initiated coverage on Henry Schein with an Overweight rating and set a price target of $86 [5] - Henry Schein's stock has increased around 6% over the past five days, reaching a 52-week high of $82.49 [5] - The RSI value for Henry Schein is 71.1, also indicating it is considered overbought [5] - Henry Schein's shares closed at $77.39, reflecting a 1.1% increase [5]

Core Insights - Avant Technologies, Inc. is focusing on cell encapsulation technology to develop long-term treatments for type 1 and insulin-dependent type 2 diabetes, addressing the limitations of traditional insulin therapies [1][4][5] - A joint venture with SGAustria Pte. Ltd. aims to innovate diabetes treatment through stem cell technology combined with encapsulation, leading to the establishment of Insulinova, Inc. for clinical trials [2][6] - The International Diabetes Federation estimates that 589 million people globally live with diabetes, with projections of 853 million by 2050, highlighting the urgent need for effective treatments [3] Company Overview - Avant Technologies is an emerging biotechnology company focused on developing cell-based therapies through genetically modified cell lines and strategic partnerships [8] - SGAustria specializes in clinically proven cell encapsulation and has a strong background with over 50 peer-reviewed publications [9] Technology and Innovation - Cell encapsulation technology, such as SGAustria's Cell-in-a-Box, protects insulin-producing cells from immune rejection, allowing for sustained insulin delivery without immunosuppression [5][6] - Recent advancements in encapsulation devices have shown promising results in controlling glucose levels and improving patient well-being, positioning Avant and SGAustria at the forefront of diabetes therapy development [6][7]

Core Insights - Humacyte, Inc. has secured a credit facility with Avenue Venture Opportunities Fund II, L.P. for up to $77.5 million, aimed at retiring existing debt and providing future financing opportunities [1][2] Financing Details - The credit agreement has a four-year term, with an initial tranche of $40 million fully funded at closing, and two additional tranches totaling up to $37.5 million contingent on certain conditions [1] - Proceeds from the initial tranche are primarily allocated to retire Humacyte's existing debt facility [1] Company Growth Plans - Humacyte plans to expand the use of its product Symvess® in both U.S. and international markets in 2026 [2] - The company anticipates interim results from its V012 Phase 3 trial in dialysis and the initiation of the first human study of its coronary tissue engineered vessel (CTEV) for coronary bypass graft surgery [2] Product Development and Regulatory Status - Humacyte is developing bioengineered human tissues and has received FDA approval for its acellular tissue engineered vessel (ATEV) for vascular trauma in December 2024 [4] - The ATEV is currently in late-stage clinical trials for other vascular applications, including arteriovenous access for hemodialysis and peripheral artery disease [4] - Preclinical development is ongoing for coronary artery bypass grafts, pediatric heart surgery, and treatment of type 1 diabetes [4] Strategic Partnerships - Avenue Venture Opportunities Fund expresses excitement in partnering with Humacyte, highlighting the significant patient needs addressed by Symvess [2][3]

IT之家 12 月 16 日消息，获 OpenAI 投资的生物技术初创企业 Chai Discovery 于当地时间本周一宣布，其 B 轮融资额达 1.3 亿美元（IT之家注：现汇率约合 9.17 亿元人民币），公司估值由此升至 13 亿美元（现汇率约合 91.73 亿元人民币）。 该公司表示，此轮融资由 General Catalyst 和 Oak HC / FT 领投。其他参与者包括 Menlo Ventures、OpenAI、Dimension、Thrive Capital、Neo、Yosemite 风险 投资基金、Lachy Groom、SV Angel，以及新投资者 Glade Brook 和 Emerson Collective。至此，该公司累计融资总额已超 2.25 亿美元（现汇率约合 15.88 亿 元人民币）。 Chai Discovery 所处的赛道正在蓬勃发展，业内普遍将人工智能视为加速药物研发的捷径。今年 8 月，Menlo Ventures 曾领投该公司 7000 万美元的 A 轮融 资，并评价 Chai Discovery 是一家专注于药物发现领域基础模型开发的初创企业，其模型可预 ...

Core Viewpoint - Immunome, Inc. is positioned for significant growth with a public offering aimed at raising $400 million to advance its cancer therapies, supported by a bullish price target from Leerink Partners of $40, indicating a potential increase of approximately 76.6% from its current price of $22.65 [1][2][5][6] Group 1: Public Offering - Immunome plans to initiate an underwritten public offering of its common stock, aiming to raise $400 million, with all shares offered directly by the company [2] - The offering is subject to market conditions and is expected to provide the necessary capital to advance its cancer therapy developments [2] Group 2: Stock Performance - The stock price of IMNM has increased by 15.74%, reaching a high of $25.30 today, marking the highest price over the past year [3] - The current market capitalization of IMNM is approximately $2.08 billion [3] - Today's trading volume for IMNM is 12.54 million shares, indicating strong investor interest [4] Group 3: Growth Potential - Leerink Partners has set a price target of $40 for IMNM, suggesting significant growth potential for the stock [1][6] - The strategic move to raise capital through a public offering aligns with the company's goal to advance its innovative cancer therapies, potentially driving future stock performance [5]

Core Viewpoint - Clearmind Medicine Inc. is implementing a reverse stock split to comply with Nasdaq regulations, which will significantly reduce its outstanding shares while maintaining authorized share capital [1][2]. Group 1: Reverse Stock Split Details - The reverse stock split will occur at a ratio of 40 for 1 on December 15, 2025, reducing outstanding shares from approximately 60 million to 1.5 million [1][2]. - The board of directors approved this decision on November 12, 2025, and no fractional shares will be issued; instead, they will be rounded up to the nearest whole share [2]. Group 2: Stock Performance - Following the announcement, CMND's share price dropped 29.92% in after-hours trading, with the stock closing at $0.11 before the announcement, reflecting a decrease of 6.08% [3]. - The current stock price is $2.61, indicating a decrease of approximately 12.14% [3]. - The stock has shown significant volatility, trading between $2.54 and $3.25 on the day of the announcement, with a yearly high of $87.20 and a low of $2.54 [4]. Group 3: Market Capitalization and Trading Volume - CMND's market capitalization is approximately $14.27 million, with a trading volume of 247,625 shares [4].

Core Insights - Nektar Therapeutics will host an investor call and live webcast to review topline results from the 36-week induction treatment period in the ongoing Phase 2b REZOLVE-AA clinical trial of rezpegaldesleukin for severe-to-very-severe alopecia areata on December 16, 2025 [1] Company Overview - Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments for autoimmune and chronic inflammatory diseases [3] - The lead product candidate, rezpegaldesleukin (REZPEG or NKTR-358), is a first-in-class regulatory T cell stimulator being evaluated in two Phase 2b clinical trials, one for atopic dermatitis and one for alopecia areata, as well as in a Phase 2 clinical trial for Type 1 diabetes mellitus [3] - Nektar's pipeline includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody, bispecific programs NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422 [3] - The company is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to enhance the immune system's ability to combat cancer, in several ongoing clinical trials [3] Event Details - The results from the clinical trial will be provided in a morning press release and presented during the webcast, which can be accessed via a provided link [2] - A replay of the webcast will be available for at least 30 days following the event [2]

Core Insights - Allogene Therapeutics has achieved a favorable arbitration outcome with Servier regarding cemacabtagene ansegedleucel (cema-cel), reaffirming its full development and commercial control in the U.S., EU, and UK, while paving the way for global commercialization rights [1][5][8] Group 1: Arbitration Outcome - The tribunal rejected Cellectis's allegations against Servier regarding development obligations and financial claims, determining that milestone payments are contingent upon FDA acceptance of a Biologics License Application (BLA) [6] - A partial termination of the license was ordered, limited to the UCART19 V1 product, and Cellectis was directed to negotiate a direct license to Allogene if pursued [6] Group 2: Future Developments - Allogene is entering 2026 with improved fundamentals and is approaching a significant catalyst period in the allogeneic CAR T field, including an interim futility analysis in 1H 2026 for cema-cel in first-line patients with large B-cell lymphoma (LBCL) [2][5]